Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

119M-1

Sigma-Aldrich

CD19 (MRQ-36) Mouse Monoclonal Antibody

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

mouse

Niveau de qualité

100
500

Conjugué

unconjugated

Forme d'anticorps

culture supernatant

Type de produit anticorps

primary antibodies

Clone

MRQ-36, monoclonal

Description

For In Vitro Diagnostic Use in Select Regions (See Chart)

Forme

buffered aqueous solution

Espèces réactives

human

Conditionnement

vial of 0.1 mL concentrate (119M-14)
vial of 0.5 mL concentrate (119M-15)
bottle of 1.0 mL predilute (119M-17)
vial of 1.0 mL concentrate (119M-16)
bottle of 7.0 mL predilute (119M-18)

Fabricant/nom de marque

Cell Marque™

Technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

Isotype

IgG1κ

Contrôle

tonsil

Conditions d'expédition

wet ice

Température de stockage

2-8°C

Visualisation

membranous

Informations sur le gène

human ... CD19(930)

Description générale

CD19 is present in both normal and malignant B-cells and has long been considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, mantle zone cells, and scattered cells in the interfollicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in immature B-cells; although recent studies have described CD19 loss in a few B-cell neoplasms.

Qualité


IVD
IVD
IVD
RUO

Liaison

CD19 Positive Control Slides, Product No. 119S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Forme physique

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Notes préparatoires

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Autres remarques

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informations légales

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000292400
0000292400

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Y K Onno Teng et al.
Arthritis and rheumatism, 56(12), 3909-3918 (2007-12-01)
Anti-CD20-mediated B cell depletion with rituximab is a new and effective therapy for rheumatoid arthritis (RA). Although B cells in peripheral blood (PB) are consistently depleted in all patients, the clinical effects are more heterogeneous, possibly related to differences in
Oliver M Steinmetz et al.
Transplantation, 84(7), 842-850 (2007-11-07)
Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently
S A Greenberg et al.
Neurology, 65(11), 1782-1787 (2005-12-14)
Previous immunohistochemical studies of muscle from patients with inclusion body myositis and polymyositis found many more T cells than B cells, suggesting a role for intramuscular cell-mediated immune mechanisms rather than humoral mechanisms. Microarray studies were performed on muscle biopsy
Miho Kimura et al.
International journal of hematology, 85(1), 41-48 (2007-01-31)
To clarify the clinicopathologic significance of a loss of CD19 expression in diffuse large B-cell lymphoma (DLBCL), we evaluated CD19 expression immunohistochemically in frozen sections from 227 patients who had received diagnoses of DLBCL according to the World Health Organization
N Masir et al.
Histopathology, 48(3), 239-246 (2006-01-25)
To investigate whether an antibody against an intracellular epitope can detect CD19 in routine biopsy specimens and thus to document in detail its expression in human lymphomas. A polyclonal antibody to the C terminus of CD19 was used to immunostain

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique